Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | August 2011 |
| End Date: | August 2017 |
Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer
This study is a phase 1/2a, open label, dose escalation and safety study of APC-100
(2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.
(2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.
Inclusion Criteria:
- Patients with histopathologically proven adenocarcinoma of the prostate
- Patients must have progressive disease
- Patients must have had prior treatment with bilateral orchiectomy or androgen
deprivation therapy with an LHRH-blocker with evidence of treatment failure
Exclusion Criteria:
- Patients treated with other secondary hormonal therapies
- Patients with prior chemotherapy given for castrate-resistant prostate cancer
- Patients with prior radiation therapy completed less than 4 weeks prior enrollment
- Patients with prior investigational therapies within 4 weeks before treatment with
APC-100
- Evidence of active second malignancy
We found this trial at
2
sites
Click here to add this to my saved trials
600 Highland Ave.
Madison, Wisconsin 53792
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Carbone Cancer Center UW Carbone Cancer Center holds the unique distinction of...
Click here to add this to my saved trials